Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.39 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.36 |
| ▸ | AKT2 | P31751 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.35 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.34 |
| ▸ | TDO2 | P48775 | 1/20 | 0.33 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.33 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7704868 | 0.83 | GSTP1 (0.49) | SMN1; SMN2PTGS2TSHR | |
| SCHEMBL7704625 | 0.83 | ALDH1A1 (0.37) | ESR2CYP2A6CYP2B6ALDH1A1HPGD | |
| SCHEMBL5795387 | 0.82 | ACHE (0.36) | BACE1ALDH1A1HSD17B10HPGDLMNA | |
| SCHEMBL8734269 | 0.79 | ACHE (0.41) | HPGDSMN1; SMN2PARP10PARP11TSHR | |
| SCHEMBL456233 | 0.78 | ESR2 (0.38) | ESR2CYP2A6CYP2B6AKT1AKT2 | |
| SCHEMBL27714313 | 0.78 | ESR2 (0.47) | ESR2CYP2A6CYP2B6AKT1AKT2 | |
| SCHEMBL456995 | 0.78 | ALDH1A1 (0.41) | ESR2CYP2A6CYP2B6AKT1AKT2 | |
| SCHEMBL6206554 | 0.78 | CYP2A6 (0.41) | ESR2CYP2A6CYP2B6AKT1AKT2 | |
| SCHEMBL457524 | 0.78 | ALDH1A1 (0.41) | ESR2CYP2A6CYP2B6AKT1AKT2 | |
| SCHEMBL14675940 | 0.78 | ESR2 (0.38) | ESR2CYP2A6CYP2B6AKT1AKT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009135600-A1 | CATALYSTS FOR THE SYNTHESIS OF POLYURETHANES | BAYER MATERIALSCIENCE AG (DE) | 2009-11-12 | — | — | WO | claimed |
| US-20240189335-A1 | N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTI-VIRAL USES RELATED THERETO | EMORY UNIVERSITY | 2024-06-13 | — | — | US | disclosed |
| US-20240180948-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY | 2024-06-06 | — | — | US | disclosed |
| US-20240165143-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY | 2024-05-23 | — | — | US | disclosed |
| WO-2024086592-A2 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNVERSITY (US) | 2024-04-25 | — | — | WO | disclosed |
| US-11903959-B2 | N4-hydroxycytidine and derivatives and anti-viral uses related thereto | EMORY UNIVERSITY (US) | 2024-02-20 | — | — | US | disclosed |
| WO-2024015916-A2 | 4'-ALKYNE-2'-DEOXYCYTIDINE-BASED COMPOUNDS AND ANTI-CANCER USES THEREOF | THOMAS JEFFERSON UNIVERSITY (US) | 2024-01-18 | — | — | WO | disclosed |
| WO-2022174179-A9 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2023-02-02 | — | — | WO | disclosed |
| CN-115666587-A | N4-hydroxycytidine and derivatives and related antiviral uses thereof | 埃默里大学 | 2023-01-31 | — | — | CN | disclosed |
| WO-2022174194-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2022-08-18 | — | — | WO | disclosed |
| US-20200276219-A1 | N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTI-VIRAL USES RELATED THERETO | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-09-03 | — | — | US | disclosed |
| WO-2019173602-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2019-09-12 | — | — | WO | disclosed |
| WO-2019113462-A1 | N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTI-VIRAL USES RELATED THERETO | EMORY UNIVERSITY (US) | 2019-06-13 | — | — | WO | disclosed |
| CN-100575351-C | Preparation of heterocyclic ketones | BASELL POLYOLEFINE GMBH | 2009-12-30 | — | — | CN | disclosed |
| WO-2009135600-A1 | CATALYSTS FOR THE SYNTHESIS OF POLYURETHANES | BAYER MATERIALSCIENCE AG (DE) | 2009-11-12 | — | — | WO | disclosed |
| EP-1697339-A1 | 3-(4-BENZYLOXYPHENYL)PROPANOIC ACID DERIVATIVES | Takeda Pharmaceutical Company Limited (JP) | 2006-09-06 | — | — | EP | disclosed |
| CN-1729184-A | Preparation of heterocyclic ketones | BASELL POLYOLEFINE GMBH (DE) | 2006-02-01 | — | — | CN | disclosed |
| WO-2005063729-A1 | 3-(4-BENZYLOXYPHENYL)PROPANOIC ACID DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-07-14 | — | — | WO | disclosed |
| US-6319702-B1 | NUCLEOTIDE SEQUENCS CODING AN ENZYMATIC POLYPEPTIDE AND CELL TARGETING COMPOUND; FOR USE IN TREATMENT OF CANCER | GLAXO WELLCOME, INC. | 2001-11-20 | — | — | US | disclosed |
| US-4952580-A | NEMATOCIDES, ANTHELMINTICS | FMC CORPORATION (US) | 1990-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11903959-B2 | N4-hydroxycytidine and derivatives and anti-viral uses related thereto | ENTPD1, NME2, NME1 | ESR2 2177/4885CYP2A6 3103/4885CYP2B6 3248/4885 |
| US-20240180948-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | PNP, PRPF4, HPRT1 | ESR2 1956/4885CYP2A6 2694/4885CYP2B6 2210/4885 |
| US-20240189335-A1 | N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTI-VIRAL USES RELATED THERETO | ENTPD1, NME2, NME1 | ESR2 2177/4885CYP2A6 3103/4885CYP2B6 3248/4885 |
| US-20240165143-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | PNP, PRPF4, HPRT1 | ESR2 1956/4885CYP2A6 2694/4885CYP2B6 2210/4885 |
| US-20200276219-A1 | N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTI-VIRAL USES RELATED THERETO | ENTPD1, NME2, NME1 | ESR2 2177/4885CYP2A6 3103/4885CYP2B6 3248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.